AI-Powered Precision for Chemotherapy Benefit Prediction

Ataraxis™ Breast CTX

Ataraxis Breast CTX is the first AI test that quantifies individualized chemotherapy benefit for early-stage HR+/HER2- breast cancer. Using H&E slides and clinical data, it reveals who truly needs chemotherapy, and which patients are unlikely to benefit, even with high recurrence risk.

For Physicians
For Patients

Why individualized prediction matters

Choosing whether to add chemotherapy to endocrine therapy in HR+, HER2– early breast cancer is one of oncology’s hardest decisions. Most tools estimate recurrence risk or average group benefit, but not patient-specific chemotherapy effect.

Risk alone can mislead treatment decisions.

Graphic showing that 1 in 4 high-risk patients are predicted to gain little from chemotherapy, illustrated by one dark figure with a red warning sign among four figures.Graphic showing one in four female icons, with one marked in dark color and a warning triangle, representing high-risk patients predicted to gain little from chemotherapy.

Real-world cohorts show the gap: about 1 in 4 “high-risk” patients is predicted to gain little from chemotherapy, while some “low-risk” patients may benefit substantially. This mismatch means some patients endure treatment with minimal personal benefit, while others who could benefit more are not readily identified. Ultimately, clinicians are left inferring individual decisions from population-level signals—an approach that falls short of true precision care.

Comparison showing two women with equal 10% recurrence risk; on the left, a woman with dark hair in a bun labeled 'High Benefit' with a check mark, on the right, a woman with a bob hairstyle labeled 'No Benefit' with an X mark.

Same recurrence risk ≠ same chemotherapy benefit.

And that difference matters.

Know, for every patient, not averages.

Going beyond averages

Infographic showing 12% of patients missed by old genomic tests have low or no chemotherapy benefit despite high risk of recurrence.
Diagram showing 12% of patients with low or no chemotherapy benefit despite high recurrence risk, suggesting alternative treatments like CDK4/6 inhibitors, ovarian function suppression, PARP inhibitors, and SERDs.
Scatter plot showing chemotherapy benefit versus risk of recurrence, highlighting a group with high risk but low chemotherapy benefit labeled as potential overtreatment group.

Reduce overtreatment. Identify non-benefiters.

Average-based decisions hide meaningful patient differences.

ATX CTX doesn’t just predict who benefits from chemotherapy—it reveals a critical subgroup of patients who appear clinically high-risk yet are unlikely to benefit from adjuvant chemotherapy. These patients are traditionally overtreated, and our test helps identify them.

Clinical application of our test

document icon
Standard adjuvant chemotherapy in patients with high estimated benefit

Ataraxis Breast CTX can identify and quantify estimated chemotherapy benefit in all HR+ HER2- patients, regardless of their risk of recurrence. Then, depending on your and patient’s preferences, identify patients who should receive adjuvant chemotherapy.

breast cancer icon
Alternative options for high-risk patients with no estimated benefit

Patients with high risk of recurrence but low or no benefit from adjuvant chemotherapy might be considered for appropriate treatment strategies such as adjuvant CDK4/6 inhibitors, ovarian function suppression, PARP inhibitors, and SERDs, improving alignment between biology and therapy.

arrow descrease icon
De-escalation for patients with no chemotherapy benefit

Find patients with low or no predicted chemotherapy benefit, including those with high recurrence risk by traditional genomic assays, and confidently spare them unnecessary toxicity and cost.

How do we predict chemotherapy benefit?

Flowchart showing how Ataraxis AI models use H&E slide and clinical data to estimate personalized 5-year recurrence risk and chemotherapy benefit, highlighting a 2% estimated chemo benefit with clinical recommendations based on the result.Flowchart showing use of H&E slide and clinical data to personalize recurrence risk and chemotherapy benefit, with examples of 7% recurrence risk with endocrine therapy alone, 2% estimated chemotherapy benefit, 5% recurrence risk with endocrine therapy plus chemotherapy, and decision paths for higher or low estimated chemo benefit.
01
Data you already have

Our platform uses the existing H&E-stained biopsy or resection slide collected during diagnosis, along with standard clinical variables such as:

  • Tumor size and nodal status
  • ER, PR, and HER2 status
  • Age and histologic subtype
02
Multimodal AI Analysis + Causal Inference

The model simulates two possible treatment scenarios—endocrine therapy only and endocrine + chemotherapy—to estimate individualized recurrence risks and calculate the absolute chemotherapy benefit.

03
Predictive Output

The model generates a novel, patient-specific predictive output not achievable through traditional prognostic models.

Each report provides:

  • 5-year recurrence risk with ET alone
  • 5-year recurrence risk with ET+CT
  • Absolute chemotherapy benefit (%)

These outputs offer a clear view of how chemotherapy is expected to change a patient’s outcome.

Proven clinical impact

Patients with predicted high benefit of adjuvant chemotherapy

Patients with predicted low or no benefit of adjuvant chemotherapy

Validated across international real-world cohorts of 3,000+ breast cancer patients, CTX stratifies patients by expected benefit from adjuvant chemotherapy. Patients predicted to have high benefit show improved recurrence-free survival when chemotherapy is added to endocrine therapy, while those predicted to have low or no benefit see no meaningful difference in outcomes with or without chemotherapy—helping clinicians tailor treatment intensity to the patient.

Make the most informed call for your patients.

Contact Us

What if you could know how much chemotherapy lowers your recurrence risk?

For many years, chemotherapy recommendations have relied on how large groups of patients responded on average—not on how you as an individual might respond. That’s why many people focus on a single risk score or cutoff (i.e., “my risk score is X, so I don’t need chemo”). But two people with the same score can experience very different benefit from chemotherapy. Traditional tools can tell you whether your overall risk of recurrence is high or low, but they can’t show whether chemotherapy is actually likely to move that risk in a meaningful way.

Comparison showing two women with equal 10% recurrence risk; on the left, a woman with dark hair in a bun labeled 'High Benefit' with a check mark, on the right, a woman with a bob hairstyle labeled 'No Benefit' with an X mark.

Same recurrence risk ≠ same chemotherapy benefit.

And that difference matters.

Know, for every patient, not averages.

Risk alone can mislead treatment decisions.

Graphic showing one in four female icons, with one marked in dark color and a warning triangle, representing high-risk patients predicted to gain little from chemotherapy.Graphic showing that 1 in 4 high-risk patients are predicted to gain little from chemotherapy, illustrated by one dark figure with a red warning sign among four figures.

Real-world studies reveal a gap: about 1 in 4 people labeled “high risk” may be expected to get little benefit from chemotherapy, while some labeled “low risk” could benefit a lot. This mismatch can mean some patients go through chemotherapy’s side effects with minimal added help, while others who might benefit most aren’t clearly identified.

Understand your likelihood of benefit—not a one-size-fits-all risk label

Using the same pathology slides already collected during your care, Ataraxis Breast CTX estimates your personal benefit from adding chemotherapy to endocrine therapy. Instead of placing you into a broad risk category, our test shows quantifiable percentage reduction in recurrence that chemotherapy is expected to offer for you specifically.

Healthcare worker wearing gloves and a mask adjusting an IV drip line in a clinical setting.

Your doctor can use this information to:

Understand to what extent chemotherapy is truly expected to help you
Avoid exposing yourself to difficult side effects if the benefit is small
Build a treatment plan that feels thoughtful, individualized, and aligned with your goals
Offer clearer, more confident recommendations during a stressful time by leveraging quantifiable results

How do we predict chemotherapy benefit?

Flowchart showing how Ataraxis AI models use H&E slide and clinical data to estimate personalized 5-year recurrence risk and chemotherapy benefit, highlighting a 2% estimated chemo benefit with clinical recommendations based on the result.Flowchart showing use of H&E slide and clinical data to personalize recurrence risk and chemotherapy benefit, with examples of 7% recurrence risk with endocrine therapy alone, 2% estimated chemotherapy benefit, 5% recurrence risk with endocrine therapy plus chemotherapy, and decision paths for higher or low estimated chemo benefit.
01
Data you already have

Our platform uses the existing H&E-stained biopsy or resection slide collected during diagnosis, along with standard clinical variables such as:

  • Tumor size and nodal status
  • ER, PR, and HER2 status
  • Age and histologic subtype
02
Multimodal AI Analysis + Causal Inference

The model simulates two possible treatment scenarios—endocrine therapy only and endocrine + chemotherapy—to estimate individualized recurrence risks and calculate the absolute chemotherapy benefit.

03
Predictive Output

The model generates a novel, patient-specific predictive output not achievable through traditional prognostic models.

Each report provides:

  • 5-year recurrence risk with ET alone
  • 5-year recurrence risk with ET+CT
  • Absolute chemotherapy benefit (%)

These outputs offer a clear view of how chemotherapy is expected to change a patient’s outcome.

Going beyond averages

Infographic showing 12% of patients missed by old genomic tests have low or no chemotherapy benefit despite high risk of recurrence.
Diagram showing 12% of patients with low or no chemotherapy benefit despite high recurrence risk, suggesting alternative treatments like CDK4/6 inhibitors, ovarian function suppression, PARP inhibitors, and SERDs.

Wondering if this test could guide your care? Contact us! We’re happy to help.

Contact Us
Copyright © 2025, ataraxis.ai, All Rights Reserved.

Empowering physicians with advanced multi-modal tools to improve treatment selection and patient outcomes.

Back To Top
Site Map
Legal